National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 84609 [2024-24543]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices reasonably close geographic proximity to the delineated borders of one of ITCN’s member tribes, as required in 45 CFR 98.61(c) and 98.83(b), and as described in the Program Instruction CCDF–ACF–PI–2022–03. As a result, OCC adjusted ITCN’s child count downward. CCDF regulations prescribe that reconsideration shall be conducted by hearing governed by 45 CFR part 99. The ACF Director of Office of Grants Policy, Latasha Abney, is the designated presiding officer. The presiding officer has authority to ‘‘modify or waive any rule in [Part 99] upon determination that no party will be unduly prejudiced and the ends of justice will thereby be served.’’ 45 CFR 99.4. 45 CFR 99.15 allows recognition of other individuals or groups as parties ‘‘if the issues to be considered at the hearing have directly caused them injury and their interests to be protected by the governing Federal statute and regulations.’’ This Federal Register notice serves as notification to other parties who may have interest in this hearing. Individuals or groups desiring to participate as parties should submit a petition in writing to presiding officer, Latasha Abney, at the address above within 15 days of publication of this notice. Such petition shall concisely state (i) Petitioner’s interest in the proceeding; (ii) Who will appear for petitioner; (iii) The issues on which petitioner wishes to participate; and (iv) Whether petitioner intends to present witnesses. A copy of the petition must also be served on ITCN Executive Director, Deserea Quintana at dquintana@itcn.org. The presiding officer will promptly determine whether each petitioner has the requisite interest and shall permit or deny participation accordingly. 45 CFR 99.22 allows parties to (a) Appear by counsel or other authorized representative, in all hearing proceedings; (b) Participate in any prehearing conference held by the presiding officer; (c) Agree to stipulations as to facts which will be made a part of the record; (d) Make opening statements at the hearing; (e) Present relevant evidence on the issues at the hearing; (f) Present witnesses who then must be available for crossexamination by all other parties; (g) Present oral arguments at the hearing; and (h) Submit written briefs, proposed findings of fact, and proposed conclusions of law, after the hearing. 45 CFR 99.23 allows that ‘‘The Department, the Lead Agency, and any individuals or groups recognized as parties shall have the right to conduct discovery (including depositions) against VerDate Sep<11>2014 18:48 Oct 22, 2024 Jkt 265001 opposing parties,’’ and that Rules 26–37 of the Federal Rules of Civil Procedure shall apply to discovery proceedings. Pursuant to 45 CFR 99.32, at the conclusion of the hearing and completion of post-hearing briefs, if any, the presiding officer shall certify the record and provide recommended finding and a proposed decision to the Assistant Secretary. Any party will then have 20 days to file exceptions and a supporting brief or statement with the Assistant Secretary. The decision of the Assistant Secretary shall be the final agency action on the matter. All written material provided by ACF, ITCN, and any other recognized party will be included in the administrative record. Megan E. Steel, ACF Certifying Officer. Administration for Children and Families. [FR Doc. 2024–23441 Filed 10–22–24; 8:45 am] BILLING CODE 4184–87–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Notice of Interest Rate on Overdue Debts Section 30.18 of the Department of Health and Human Services’ claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest, which is determined and fixed by the Secretary of the Treasury after considering private consumer rates of interest on the date that the Department of Health and Human Services becomes entitled to recovery. The rate cannot be lower than the Department of Treasury’s current value of funds rate or the applicable rate determined from the ‘‘Schedule of Certified Interest Rates with Range of Maturities’’ unless the Secretary waives interest in whole or part, or a different rate is prescribed by statute, contract, or repayment agreement. The Secretary of the Treasury may revise this rate quarterly. The Department of Health and Human Services publishes this rate in the Federal Register. The current rate of 123⁄8%, as fixed by the Secretary of the Treasury, is certified for the quarter ended September 30, 2024. This rate is based on the Interest Rates for Specific Legislation, ‘‘National Health Services Corps Scholarship Program (42 U.S.C. 254o(b)(1)(A))’’ and ‘‘National Research Service Award Program (42 U.S.C. 288(c)(4)(B)).’’ This interest rate will be applied to overdue PO 00000 Frm 00089 Fmt 4703 Sfmt 9990 84609 debt until the Department of Health and Human Services publishes a revision. David C. Horn, Director, Office of Financial Policy and Reporting. [FR Doc. 2024–24510 Filed 10–22–24; 8:45 am] BILLING CODE 4150–04–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01—Clinical Trial Not Allowed). Date: November 22, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E72A, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Frank S. De Silva, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E72A, Rockville, MD 20892, (240) 669–5023, fdesilva@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: October 18, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–24543 Filed 10–22–24; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\23OCN1.SGM 23OCN1

Agencies

[Federal Register Volume 89, Number 205 (Wednesday, October 23, 2024)]
[Notices]
[Page 84609]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24543]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; Feasibility of Novel Diagnostics 
for TB in Endemic Countries (FEND for TB) (R01--Clinical Trial Not 
Allowed).
    Date: November 22, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E72A, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Frank S. De Silva, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E72A, 
Rockville, MD 20892, (240) 669-5023, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 18, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-24543 Filed 10-22-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.